


## Utilization des antiviraux pour les orthopoxviruses

Robert Snoeck  
Rega Institute for Medical Research  
Katholieke Universiteit Leuven, Leuven, Belgium



Activity of selected ANPs against Vaccinia virus (Lederle strain) in HEL cells

Compound	IC <sub>50</sub> (µg/ml)	CC <sub>50</sub> (µg/ml)	MCC (µg/ml)	Selectivity index
HPMPC (cidofovir)	3.57	37.9	>50	10.6
cHPMPC	4.74	>50	>50	>10.6
HPMPA	0.17	2.4	>20	14.1
3-deaza-HPMPA	0.78	3.2	20	4.1
cHPMPA	0.39	13.8	>20	35.4
HPMPDAP	0.51	25.3	>50	49.6
HPMPO-DAPY	0.76	10.9	>50	14.3
PMEA	>50	31.1	>50	<0.62
PMEDAP	>50	18.0	>50	<0.36
PMEO-DAPY	31.75	27.9	>50	0.88

Activity of selected ANPs against Vaccinia virus (Lederle strain) in PHK cells







Compound	IC <sub>50</sub> (µg/ml)	CC <sub>50</sub> (µg/ml)	MCC (µg/ml)	Selectivity index
HPMPC (Cidofovir)	3.01	3.3	>50	1.1
cHPMPC	11.9	7.6	>50	0.64
HPMPA	0.92	1.3	>20	1.4
3-deaza-HPMPA	0.4	0.7	>20	1.8
cHPMPA	1.94	9.1	>20	4.7
HPMPDAP	0.84	3.4	>50	4.1
HPMPO-DAPY	1.55	6.3	>50	4.1
PMEA	>50	57.7	>50	<1.2
PMEDAP	26	6.4	>50	0.25
PMEO-DAPY	13.5	8.1	>50	0.6





Activity of selected ANPs against Cowpox virus (Brighton strain) in HEL cells

Compound	IC <sub>50</sub> (µg/ml)	CC <sub>50</sub> (µg/ml)	MCC (µg/ml)	Selectivity index
HPMPC (Cidofovir)	4.6	37.9	>50	8.3
cHPMPC	4.33	>50	>50	>11.5
HPMPA	0.23	2.4	>20	10.7
3-deaza-HPMPA	2.31	3.2	20	1.37
cHPMPA	0.55	13.8	>20	25.4
HPMPDAP	0.75	25.3	>50	33.8
HPMPO-DAPY	1.65	10.9	>50	6.6
PMEA	>50	31.1	>50	<0.6
PMEDAP	>50	18.0	>50	<0.4
PMEO-DAPY	39.17	27.9	>50	<0.5

Activity of selected ANPs against Cowpox virus (Brighton strain) in PHK cells

Compound	IC <sub>50</sub> (µg/ml)	CC <sub>50</sub> (µg/ml)	MCC (µg/ml)	Selectivity index
HPMPC (Cidofovir)	6.03	3.3	>50	0.6
cHPMPC	15.3	7.6	>50	0.5
HPMPA	1.69	1.3	>20	0.8
3-deaza-HPMPA	2.25	0.66	>20	0.3
cHPMPA	2.98	9.08	>20	3.0
HPMPDAP	1.56	3.43	>50	2.2
HPMPO-DAPY	2.86	6.27	>50	2.2
PMEA	>50	57.70	>50	<1.15
PMEDAP	>50	6.35	>50	<0.13
PMEO-DAPY	26.9	8.12	>50	0.3





**Activity of several ANPs against plaque-purified Vaccinia Virus mutants (strain Lederle) resistant to HPMPC in HEL cells**

Strain	Mean IC <sub>50</sub> (µg/ml)							
	HPMPC	HPMPA	3-deazaHPMPA	HPMPDAP	cHPMPC	cHPMPA	HPMPO-DAPY	
HPMPC clone 1	15.5	0.69	0.74	2.3	23	1.67	9.6	24
HPMPC clone 2	11.5	0.7	0.57	2.3	14.5	1.33	6.7	21
HPMPC clone 3	16.5	1.8	1.27	9.13	30.8	7.72	15.3	26
HPMPC clone 4	14.9	1.75	1.01	6.23	25.5	6.85	7.7	21
HPMPC clone 5	15.9	1.3	1.17	7.2	28.8	5.72	8.3	28
HPMPC clone 6	15.1	0.91	0.88	5.9	27.4	6.13	9.0	31
HPMPC clone 7	13.0	1.17	1.0	5.6	23	4.36	4.2	21
wild-type clone 1	2.5	0.14	0.46	0.3	3.2	0.24	0.93	30
wild-type clone 2	1.8	0.095	0.32	0.28	3.9	0.39	0.9	25

**Activity of several ANPs against Vaccinia Virus mutants (strain Lederle) resistant to c-HPMPC, HPMPA and c-HPMPA in HEL cells**

Strain	Mean IC <sub>50</sub> (µg/ml)						
	HPMPC	HPMPA	3-deazaHPMPA	HPMPDAP	cHPMPC	cHPMPA	HPMPO-DAPY
cHPMPC	6.7	1.13	0.53	5.7	14.2	3.6	14.7
HPMPA	6	0.96	0.46	4.5	14.8	2.2	7.4
cHPMPA	7.6	1.45	0.32	4.2	7.5	2.3	7.0
3-deazaHPMPA	2.4	0.14	0.61	0.4	5.3	0.38	0.9
wildtype	2.4	0.06	0.32	0.23	3.4	0.3	0.73

## Acknowledgements

Graciela Andrei  
Joos van den Oord  
Fabiana Dal Pozzo  
Tina De Raeve  
Erik De Clercq